NASDAQ:TGTXTG Therapeutics Stock Price, Forecast & News

TG Therapeutics' stock was trading at $10.01 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, TGTX shares have increased by 86.3% and is now trading at $18.65. View which stocks have been most impacted by Coronavirus.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TG Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for TG Therapeutics.

TG Therapeutics is scheduled to release its next quarterly earnings announcement on Friday, August 14th 2020. View our earnings forecast for TG Therapeutics.

TG Therapeutics Inc (NASDAQ:TGTX) issued its earnings results on Monday, May, 11th. The biopharmaceutical company reported ($0.48) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.36) by $0.12. The biopharmaceutical company had revenue of $0.04 million for the quarter, compared to analyst estimates of $0.04 million. TG Therapeutics had a negative return on equity of 2,937.74% and a negative net margin of 124,230.27%. View TG Therapeutics' earnings history.

3 Wall Street analysts have issued twelve-month price targets for TG Therapeutics' stock. Their forecasts range from $32.00 to $37.00. On average, they anticipate TG Therapeutics' stock price to reach $34.67 in the next twelve months. This suggests a possible upside of 85.9% from the stock's current price. View analysts' price targets for TG Therapeutics.

Headlines about TGTX stock have trended very negative recently, InfoTrie Sentiment Analysis reports. InfoTrie scores the sentiment of media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. TG Therapeutics earned a coverage optimism score of -3.5 on InfoTrie's scale. They also gave media coverage about the biopharmaceutical company a news buzz of 9.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the next several days. View the latest news aboutTG Therapeutics.

Some companies that are related to TG Therapeutics include Elanco Animal Health (ELAN), Dr.Reddy's Laboratories (RDY), ACADIA Pharmaceuticals (ACAD), Ionis Pharmaceuticals (IONS), Perrigo (PRGO), Ascendis Pharma A/S (ASND), Bausch Health Companies (BHC), Jazz Pharmaceuticals (JAZZ), United Therapeutics (UTHR), Reata Pharmaceuticals (RETA), Myokardia (MYOK), Forty Seven (FTSV), Mirati Therapeutics (MRTX), Emergent Biosolutions (EBS) and BridgeBio Pharma (BBIO). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other TG Therapeutics investors own include Novavax (NVAX), AK Steel (AKS), Micron Technology (MU), Amarin (AMRN), UrtheCast (UR), Gilead Sciences (GILD), BioDelivery Sciences International (BDSI), AcelRx Pharmaceuticals (ACRX), Cara Therapeutics (CARA) and Synergy Pharmaceuticals (SGYP).

TG Therapeutics trades on the NASDAQ under the ticker symbol "TGTX."

TG Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include RA Capital Management L.P. (9.43%), BlackRock Inc. (5.58%), State Street Corp (3.17%), Geode Capital Management LLC (1.22%), Lord Abbett & CO. LLC (0.86%) and Nuveen Asset Management LLC (0.57%). Company insiders that own TG Therapeutics stock include Michael S Weiss, Sean A Power and William James Kennedy. View institutional ownership trends for TG Therapeutics.

TGTX stock was sold by a variety of institutional investors in the last quarter, including Sofinnova Investments Inc., Rafferty Asset Management LLC, JPMorgan Chase & Co., Raymond James & Associates, Wells Fargo & Company MN, Frontier Wealth Management LLC, HighTower Advisors LLC, and Raymond James Financial Services Advisors Inc.. View insider buying and selling activity for TG Therapeutics.

TGTX stock was purchased by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, RA Capital Management L.P., Nuveen Asset Management LLC, Geode Capital Management LLC, Ghost Tree Capital LLC, Federated Hermes Inc., State Street Corp, and BlackRock Inc.. View insider buying and selling activity for TG Therapeutics.

Shares of TGTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of TGTX stock can currently be purchased for approximately $18.65.

TG Therapeutics has a market capitalization of $2.05 billion and generates $150,000.00 in revenue each year. The biopharmaceutical company earns $-172,870,000.00 in net income (profit) each year or ($1.83) on an earnings per share basis. TG Therapeutics employs 105 workers across the globe.

The official website for TG Therapeutics is www.tgtherapeutics.com.

TG Therapeutics' mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The biopharmaceutical company can be reached via phone at 212-554-4484 or via email at [email protected]